Current Topics in Nonclinical Drug Development : Volume 3
Language: English
Published by Taylor & Francis Ltd Okt 2026, 2026
- Hardcover
- New
Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH
AbeBooks seller since August 14, 2006
Condition: New
US$ 377.61
Quantity: 2 available
Add to basketItem description from seller
Neuware - This third volume in the series focuses on such germane issues as the weight of evidence approach, applying the 3Rs (replacement, reduction, and refinement), personalized drug therapies, and oncology therapeutics, among others. Volumes in this series are aimed at toxicologists, toxicologic pathologists, regulators, and study directors dealing with issues in study design, evaluation of findings, and presentation of data. In addition, the series will serve as an aid to academicians and graduate students studying nonclinical drug development.Key Features: - Explores the critical issues and current topics important in nonclinical drug development - Deals with day-to-day issues in study design, evaluation of findings, and presentation of data - Aids academicians and graduate students pursuing research related to nonclinical drug development - Delves into both the art and science of nonclinical drug development and its impact on translational medicine and human safety.
Seller Inventory # 9781032803500
- Title
- Current Topics in Nonclinical Drug Development : Volume 3
- Author
- Philip Bentley
- Publisher
- Taylor & Francis Ltd Okt 2026
- Publication year
- 2026
- Condition
- Neu
- Binding
- Buch
- Language
- English
- ISBN 10
- 1032803509
- ISBN 13
- 9781032803500
- Dimensions
- 254x178x38 mm
This third volume in the series focuses on such germane issues as the weight of evidence approach, applying the 3Rs (replacement, reduction, and refinement), personalized drug therapies, and oncology therapeutics, among others. Volumes in this series are aimed at toxicologists, toxicologic pathologists, regulators, and study directors dealing with issues in study design, evaluation of findings, and presentation of data. In addition, the series will serve as an aid to academicians and graduate students studying nonclinical drug development.
Key Features:
- Explores the critical issues and current topics important in nonclinical drug development
- Deals with day-to-day issues in study design, evaluation of findings, and presentation of data
- Aids academicians and graduate students pursuing research related to nonclinical drug development
- Delves into both the art and science of nonclinical drug development and its impact on translational medicine and human safety
"Synopsis" may belong to another edition of this title.
About the Author
Zbigniew W. Wojcinski is President of Toxicology & Pathology Consulting, LLC, in Ann Arbor, MI and has over 30 years’ experience in drug development. Dr. Wojcinski received his undergraduate degree (B.Sc.) in Zoology from the University of Toronto and his D.V.M. and D.V.Sc. (Pathology) degrees from the Ontario Veterinary College, University of Guelph. He is a certified Diplomate of the American Board of Toxicology and a Diplomate of the American College of Veterinary Pathologists. He is also recognized as a Specialist in Veterinary Pathology by the Canadian Veterinary Medical Association. Dr. Wojcinski gained experience in drug development and toxicologic pathology during his 22-year tenure with Parke-Davis\Warner-Lambert and Pfizer Global Research and Development and then 3½ years with Fulcrum Pharma Developments, Inc. In 2011, he founded Drug Development Pathology Services, LLC in Ann Arbor, MI and subsequently grew the organization into Drug Development Preclinical Services, LLC to provide toxicology, pathology, and drug metabolism and pharmacokinetic services. Dr. Wojcinski has extensive experience as a Study Director, Study Pathologist, and Review Pathologist for numerous acute and repeated dose toxicity studies, including carcinogenicity studies. Throughout his career, he has managed successful cross-functional drug development teams in CNS, Metabolic Diseases, and Dermatology therapeutic areas. As Therapeutic Area Leader for Dermatology at Pfizer, Dr. Wojcinski was responsible for development and implementation of the safety and risk management strategies for, what was then, a new therapeutic area. He has also been directly involved in the preparation of pre-IND documents, Nonclinical Safety Assessments for IND/IMPD/NDA/MAA, Investigator’s Brochures, and labeling (USPI, SmPC) negotiations in CNS, anti-infective, and dermatology therapeutic areas. Dr. Wojcinski has had numerous interactions with regulatory agencies in the United States, Europe, Canada, and Australia for compounds at various stages of development. He has also provided pathology consultation and histopathology peer review on several projects in various therapeutic areas, including respiratory infections, dermatitis, and ophthalmic disease and served on Pathology Working Groups. Dr. Wojcinski is a full member of numerous professional societies including the American College of Veterinary Pathologists, Society of Toxicologic Pathologists, Society of Toxicology, American College of Toxicology, American Veterinary Medical Association, Canadian Veterinary Medical Association, Canadian Association of Veterinary Pathologists, Regulatory Affairs Professionals Society, and Roundtable of Toxicology Consultants. He has served as President of the Dermal Toxicity Specialty Section of the Society of Toxicology, an Associate Editor for the Society of Toxicologic Pathology, Editor of The Scope for the Society of Toxicologic Pathology, and Chair of the Society of Toxicologic Pathology Recruitment Subcommittee. Dr. Wojcinski has lectured at the Ontario Veterinary College and the University of Maryland and authored/co-authored numerous scientific reports, manuscripts, and book chapters. Most recently, he was Co-Editor for The Illustrated Dictionary of Toxicologic Pathology & Safety Science, First Edition, 2019.
Philip Bentley is Principal Consultant at Toxicodynamix International LLC. He studied biochemistry at the University of Hull, UK, graduating with a BSc in 1970 and a PhD in 1974. He had postdoctoral fellowships at the Universities of Basel. Switzerland and Mainz, Germany. His postdoctoral research centered upon formation and inactivation of reactive metabolites and the enzymes involved in the metabolism of foreign compounds. In 1979 he joined the Investigative Toxicology group (known as Cell Biology) in the Toxicology Department of Ciba-Geigy, Basel, Switzerland and remained with the company, later Novartis, until 2014. In these 35 years he held various management positions in Europe and the USA with responsibility for Investigative Toxicology; Drug Metabolism; Drug Metabolism and Toxicology; Preclinical Safety Europe; Drug Metabolism and Pharmacokinetics; Toxicology/Pathology USA; Preclinical Safety USA and Global Preclinical Safety. In these positions he contributed to the registration of more than 45 marketed drug products and the preparation of several hundred IND’s. He has vast experience in the areas of drug metabolism and disposition, toxicology/pathology, genetic toxicology, pharmacokinetics/toxicokinetics and all aspects of investigative toxicology. He is well grounded in biochemistry, cell biology, molecular biology and pharmacology with the ability to integrate data from the different preclinical disciplines to enable translation to determine the clinical relevance of the findings. He is very familiar with global drug registration requirements and working on global projects. He has authored more than 80 scientific publications, has lectured in toxicology at the University of Basel for more than 30 years, and is a past President of the European Society of Biochemical Pharmacology and the Swiss Society of Toxicology. He was a member of the PhRMA/IQ Preclinical Leadership (DruSafe) Committee for 16 years, a member of the advisory board of the PSTC Biomarker consortium and a member of the expert working group for revision of the ICH S2 guidance on genotoxicity testing and the PhRMA expert group on genotoxic impurities.
Pritam S. Sahota, Global ToxPath LLC, Kennewick, Washington, USA has extensive experience in toxicologic pathology and drug development within the framework of nonclinical safety assessment of pharmaceuticals. Dr. Sahota was previously Executive Director and Head of Pathology, Preclinical Safety, at Novartis Pharmaceuticals, East Hanover, New Jersey. He obtained his veterinary medicine (BVSc) and veterinary pathology degrees (MSc and PhD) from Punjab Agricultural University, India. He is a Diplomate of the American Board of Toxicology. After receiving his PhD in 1976, he started working as a toxicologic pathologist at Dawson Research Corporation (DRC), Orlando, Florida, a contract research organization involved in the preclinical safety evaluation of drugs and chemicals. At DRC, he received increasing responsibility over the next 10 years (Toxicologic Pathologist, Senior Toxicologic Pathologist, and Scientific Director). As a Scientific Director, he was responsible for the scientific aspects of pathology as well as toxicology at DRC. While working briefly for Dynamac Corporation, Research Triangle Park, North Carolina (1986-87), he conducted retrospective scientific audits of 23 NTP carcinogenicity studies and participated in discussions with the representatives of NTP, FDA, and EPA to review the results of scientific audits of over 200 NTP carcinogenicity studies. In 1987, he joined Ciba-Geigy Pharmaceuticals in New Jersey as Head/Manager of pathologists in preclinical safety and was also responsible for establishing pathology peer review, quality control and scheduling systems. He continued to work primarily in this position with increasing responsibilities at Ciba-Geigy and then Novartis Pharmaceuticals (after Ciba-Sandoz merger in 1997) to become director and eventually Executive Director and Head of pathology. During this time, he also served as an international project team representative for a number of successfully marketed CNS, immunosuppression, diabetes, and cardiovascular drugs, including Diovan, which eventually became one of the 15 all-time, best-selling prescription drugs. He also held an adjunct academic appointment of Assistant Professor at the University of Medicine and Dentistry, New Jersey, for 8 years. He successfully led several global preclinical safety initiatives at Novartis, including patient centricity, review of best practices in cardio-toxicity and ocular toxicity as well as evaluation of rodent carcinogenicity potential based on non-carcinogenicity data to minimize future delays in regulatory submissions. Since retirement from Novartis Pharmaceuticals in 2012, Dr. Sahota has been the President of Global ToxPath LLC located in Kennewick, WA, USA (Toxicologic Pathology Consultancy). As Lead Editor, he published following books with CRC Press/Taylor & Francis: (1) Toxicologic Pathology: Nonclinical Safety Assessment, First Edition, 2013; (2) Toxicologic Pathology: Nonclinical Safety Assessment, Second Edition, 2018; and The Illustrated Dictionary of Toxicologic Pathology & Safety Science, First Edition, 2019.
"About the title" may belong to another edition of this title.
Shipping rates from Germany to U.S.A.
| Item | 7 to 10 business days | 5 to 7 business days |
|---|---|---|
| First item | US$ 39.18 | US$ 50.38 |
Payment methods
- Bank Wire Transfer
- Check
- Paypal
Store description
Das Unternehmen AHA-BUCH GmbH: Seit der Gründung von AHA-BUCH im Juli 2005 ist unser Hauptziel, zufriedenen Kunden so schnell und so preisgünstig wie möglich ihren Bücherwunsch zu erfüllen. Unsere Firma beschäftigt 16 Mitarbeiter, die nur ein Ziel kennen: den Kunden und seine Wünsche! Auf über 3700 m2 Fläche haben wir über 100.000 Bücher, Modernes Antiquariat und Spiele auf Lager.
Specialty
Kinderbücher & Kinderhör Casetten, German Books, Software, Natur & Tiere, Ratgeber, Sachbücher, Englische Bücher, Medizin & Gesundheit, Universität & StudiumSeller's business information
AHA-BUCH GmbH
Garlebsen 48
Einbeck, Germany 37574
Terms of sale
General Terms and Conditions and Customer Information / Privacy Policy
I. General Terms and Conditions
§ 1 Basic provisions
(1) The following terms and conditions apply to all contracts that you conclude with us as a provider (AHA-BUCH GmbH) via the Internet platforms AbeBooks and/or ZVAB. Unless otherwise agreed, the inclusion of any of your own terms and conditions used by you will be objected to
(2) A consumer within the meaning of the following regulations is any natural person who concludes a legal transaction for purposes that can predominantly be attributed neither to their commercial nor their independent professional activity. An entrepreneur is any natural or legal person or a partnership with legal capacity who, when concluding a legal transaction, acts in the exercise of his independent professional or commercial activity.
§ 2 Conclusion of the contract
(1) The object of the contract is the sale of goods.
(2) If an article is listed by us at AbeBooks or ZVAB, the activation of the offer page at AbeBooks or ZVAB constitutes the binding offer to conclude a contract under the conditions contained in the article page.
(3) The contract is concluded via the online shopping cart system as follows:
The goods intended for purchase are stored in the "shopping cart". Via the corresponding button in the navigation bar you can call up the "shopping cart" and make changes there at any time.
After calling up the "Checkout" page and entering the personal data as well as the payment and shipping conditions, all order data will be displayed again on the order overview page.
Before sending the order, you have the option of checking all information again, changing it (also via the "back" function of the Internet browser) or cancelling the purchase.
By submitting the order via the "Buy now" button, you declare the acceptance of the offer in a legally binding manner, whereby the contract is concluded.
(4) The processing of the order and transmission of all information required in connection with the conclusion of the contract is partly automated by e-mail. You must therefore ensure that the e-mail address you have stored with us is correct, that the receipt of the e-mails is technically ensured and, in particular, that spam filters do not prevent it.
§ 3 Right of retention, retention of title
(1) You can only exercise a right of retention if it concerns claims from the same contractual relationship.
(2) The goods remain our property until full payment of the purchase price.
§ 4 Warranty
(1) The statutory warranty rights exist.
(2) In the case of used goods, the warranty period is one year from delivery of the item, deviating from the statutory regulation. The shortening of the deadline does not apply:
- culpably caused damages attributable to us from injury to life, limb or health and in the case of other damages caused intentionally or through gross negligence;
- insofar as we have fraudulently concealed the defect or have assumed a guarantee for the quality of the item.
(3) As a consumer, you are requested to check the item immediately upon delivery for completeness, obvious defects and transport damage and to inform us and the freight forwarder of any complaints as soon as possible. If you do not comply with this, this will have no effect on your statutory warranty claims.
§ 5 Choice of law, place of performance, place of jurisdiction
(1) German law shall apply. In the case of consumers, this choice of law shall only apply insofar as this does not withdraw the protection afforded by mandatory provisions of the law of the state of the consumer's habitual residence (principle of favourability).
(2) The place of performance for all services arising from the existing business relationships with us as well as the place of jurisdiction is our registered office, insofar as you are not a consumer, but a merchant, a legal entity under public law or a special fund under public law. The same applies if you do not have a general place of jurisdiction in Germany or the EU or if the domicile or habitual residence is not known at the time the action is brought. The right to appeal to the court at another statutory place of jurisdiction remains unaffected by this.
(3) The provisions of the UN Convention on Contracts for the International Sale of Goods shall expressly not apply.
II. Customer Information
- Identity of the Seller
AHA-BUCH GmbH
Garlebsen 48
D-37574 Einbeck
Germany
Telephone: 055639996039
E-mail: abebooks@aha-buch.de.
Alternative dispute resolution:
The European Commission provides a platform for out-of-court online dispute resolution (ODR platform), which can be accessed under https://ec.europa.eu/odr.
- Information on the conclusion of the contract
The technical steps for the conclusion of the contract, the conclusion of the contract itself and the correction options are carried out in accordance with the provisions "Conclusion of the contract" of our General Terms and Conditions (Part I.).
- Contract language, contract text storage
3.1. The contract language is german.
3.2. The complete text of the contract will not be stored by us. Before sending the order, the contract data can be printed out or electronically saved via the print function of the browser. After receipt of the order by us, the order data, the legally prescribed information for distance contracts and the General Terms and Conditions will be sent to you again by e-mail.
- Essential characteristics of the goods or services
The essential characteristics of the goods and/or services can be found in the respective offer.
- Prices and terms of payment
5.1. The prices stated in the respective offers as well as the shipping costs represent total prices. They include all price components including all applicable taxes.
5.2. The shipping costs incurred are not included in the purchase price. They can be called up via a correspondingly designated button on our website or in the respective offer, are shown separately in the course of the ordering process and are to be borne by you in addition, unless free shipping has been promised.
5.3. If the delivery is made to countries outside the European Union, we may incur additional costs for which we are not responsible, such as.B customs duties, taxes or money transfer fees (transfer or exchange rate fees of the credit institutions), which are to be borne by you. Any costs incurred for the transfer of money shall also be borne by you in cases where the delivery is made to an EU member state, but the payment was initiated outside the European Union.
5.4. The payment methods available to you are indicated under a corresponding button on our website or in the respective offer.
5.5. Unless otherwise stated for the individual payment methods, the payment claims from the concluded contract are due for payment immediately.
- Terms of delivery
6.1. The terms of delivery, the delivery date and, if applicable, existing delivery restrictions can be found under a correspondingly designated button on our website or in the respective offer.
Insofar as no other deadline is specified in the respective offer or under the correspondingly designated button, the delivery of the goods will take place within 3-5 days after conclusion of the contract (in the case of agreed advance payment, however, only after the time of your payment instruction).
6.2. Insofar as you are a consumer, it is regulated by law that the risk of accidental loss and accidental deterioration of the sold item during dispatch shall only pass to you upon handover of the goods, regardless of whether the shipment is insured or uninsured. This does not apply if you have independently commissioned a transport company not named by the entrepreneur or a person otherwise designated to carry out the shipment.
- Statutory liability for defects
Liability for defects is governed by the "Warranty" provision in our General Terms and Conditions (Part I).
last update: 01/06/2022
Privacy policy
Unless otherwise stated below, the provision of your personal data is neither required by law or contract, nor is it necessary for the conclusion of a contract. You are not obliged to provide the data. Failure to provide this will have no consequences. This only applies if no other information is provided in the subsequent processing operations.
Collection, processing and disclosure of personal data when placing orders
When ordering, we collect and process your personal data only to the extent necessary to fulfil and process your order and to process your enquiries. The provision of the data is necessary for the conclusion of the contract. Failure to provide this provision means that no contract can be concluded. The processing takes place on the basis of Art. 6 para. 1 lit.b GDPR and is necessary for the performance of a contract with you.
Your data will be passed on, for example, to the shipping companies and dropshipping providers selected by you, payment service providers, service providers for order processing and IT service providers.
In all cases, we strictly observe the legal requirements. The scope of data transmission is limited to a minimum.
Duration of storage
After completion of the contract, the data will first be stored for the duration of the warranty period, then taking into account legal, in particular tax and commercial retention periods and then deleted after expiry of the period, unless you have consented to further processing and use.
Rights of the data subject
If the legal requirements are met, you have the following rights under Articles 15 to 20 GDPR: Right to information, to correction, to erasure, to restriction of processing, to data portability.
In addition, pursuant to Article 21 (1) GDPR, you have the right to object to processing based on Article 6 (1) f GDPR and to processing for direct marketing purposes.
Contact us on request. The contact details can be found in our imprint.
Right to lodge a complaint with the supervisory authority
In accordance with Article 77 GDPR, you have the right to complain to the supervisory authority if you believe that the processing of your personal data is not lawful.
Right to object
If the personal data processing listed here is based on our legitimate interest pursuant to Art. 6 para. 1 lit. f GDPR, you have the right to object to this processing at any time with effect for the future for reasons arising from your particular situation.
Shipping terms
We ship your order after we received them
for articles on hand latest 24 hours,
for articles with overnight supply latest 48 hours.
In case we need to order an article from our supplier our dispatch time depends on the reception date of the articles, but the articles will be shipped on the same day.
Our goal is to send the ordered articles in the fastest, but also most efficient and secure way to our customers.